Harvard-wide Program on Antibiotic Resistance

哈佛大学抗生素耐药性计划（HPAR）代表了一套紧密的合作计划， 研究项目，以解决在美国的主要公共卫生问题之一-抗生素耐药性金黄色葡萄球菌的传播作为一个主要原因，严重感染的社区，以及在 跑 医院的由临床、基础和转化科学家组成的一个有凝聚力的多学科小组推进，该计划项目提案的主题是“开发对抗MRSA感染的新方法， 并限制抗生素耐药性的发展和传播。“该团队的专业知识包括高通量筛选/后续化学，生物化学，分子生物学/遗传学， 分子发病机制到临床微生物学。研究人员都是各自领域的领导者，并带来了跨越哈佛大学马萨诸塞州总医院，哈佛医学院，哈佛学院和谢彭斯眼科研究所的机构的观点和资产-承担。该计划项目的目标是利用多学科的观点， == 采用假设驱动和发现相结合的方法，以促进对沙门氏菌抗生素耐药性的发展（子项目1：Hooper）和传播（子项目2：Gilmore）的更好理解。 金黄色;并确定新的化合物、靶标和途径，以损害微生物与宿主的相互作用（子项目3：步行者;子项目4：Ausubel/Mylonakis [均与Hooper和Gilmore合作]）。整个项目由行政核心（核心A）组织在一起，每个项目由其他项目利用，核心A将由一名具有丰富行政经验的P1领导。HPAR是专门设计来协同和利用内部和外部的倡议，包括哈佛大学范围内的微生物科学倡议和催化剂临床和转化 科学中心和NIAID NARSA计划。 FD' 7“o VII o“。 `--

The Harvard-wide Program on Antibiotic Resistance (HPAR) represents a tightly knit set of collaborative research projects to address one of the leading public health issues in the US -- the spread of antibiotic resistant Staphylococcus aureus as a leading cause of serious infection in the community as well as in ran hospitals. Advanced by a cohesive, multi-disciplinary group of clinical, basic and translational scientists, the theme of this Program Project proposal is to "Derive new approaches for combating MRSA infection, and limiting the development and spread of antibiotic resistance." The expertise of this team ranges from high throughput screening/follow up chemistry, biochemistry, molecular biology/genetics, and molecular pathogenesis to clinical microbiology. The investigators are all among leaders in their respective fields, and bring the perspectives and assets of institutions spanning Harvard University Massachusetts General Hospital, Harvard Medical School, Harvard College, and Schepens Eye Research Institute - to bear. The goal of this Program Project is to capitalize on multi-disciplinary perspectives, =�. and to take both hypothesis driven and discovery approaches, to advance a better understanding of the development (Subproject 1: Hooper) and spread (Subproject 2: Gilmore) of antibiotic resistance in S. aureus; and to identify novel compounds, targets and pathways to compromise the microbe in its interaction with the host (Subproject 3: walker; Subproject 4: Ausubel/Mylonakis [both in collaboration with Hooper and Gilmore]). The entire project is held together, with each project being leveraged by the others, by the Administrative Core (Core A), which will be led by a P1 with considerable administrative experience. The HPAR is specifically designed to synergize and leverage internal and external initiatives, including the Harvard-wide Microbial sciences Initiative and the Catalyst Clinical and Translational Science Center, and the NIAID NARSA program. FD' 7"o vii o'". `-�